Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Ceftin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

67 API Suppliers, 38 USDMF, 20 CEP/COS, 1 JDMF, 8 EU WC, 22 KDMF, 4 NDC API, 16 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

FINISHED DOSAGE FORMULATIONS

291 FDF Dossiers, 34 FDA Orange Book, 148 Europe, 7 Canada, 9 South Africa, 93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML, FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

RELATED EXCIPIENT COMPANIES

3 Evonik, 4 Rochem International Inc, 20 SPI Pharma, 9 DKSH, 1 Pharm-RX Chemical, 3 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 Kirsch Pharma, 1 ACG Worldwide, 8 Actylis, 2 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 19 BASF, 1 CD Formulation, 2 Clariant, 12 Corel Pharma Chem, 3 DFE Pharma, 1 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 8 Ideal Cures, 4 Ingredion Pharma Solutions, 11 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 20 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

61 Fillers, Diluents & Binders, 52 Coating Systems & Additives, 31 Thickeners and Stabilizers, 30 Direct Compression, 26 Lubricants & Glidants, 26 Controlled & Modified Release, 24 Solubilizers, 23 Taste Masking, 21 Disintegrants & Superdisintegrants, 21 Topical, 21 Chewable & Orodispersible Aids, 19 Granulation, 18 Parenteral, 15 Film Formers & Plasticizers, 15 Co-Processed Excipients, 11 Emulsifying Agents, 10 Rheology Modifiers, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents

DIGITAL CONTENT

14 News #PharmaBuzz

14 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 29 Regulatory FDF Prices

MARKET PLACE

26 APIs, 30 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 7 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Aurobindo Pharma Limited	India	International Pharmaceutical Co., Ltd.	20050915-22-A-166-06(8)	cefuroxime axetil	2014-07-25	AUROBINDO PHARMA LTD	India	Unit-I, Survey No. 385, 386, 388 - 396, Borpatla village, Hatnoora Mandal Medak District, Telangana, INDIA.
29/11/2025	Aurobindo Pharma Limited	India	Daewoong Pharmaceutical Co., Ltd.	20050915-22-A-166-06(2)	cefuroxime axetil	2011-07-15	Aurobindo Pharma ltd.	India	Unit-1, Sy. No. 379, 385, 386, 388 to 396, Borpatla(V), Hatnoora(M), Sanga Reddy District, Telangana, India

Ceftin

Ceftin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

67 API Suppliers

38 USDMF

20 CEP/COS

1 JDMF

8 EU WC

22 KDMF

4 NDC API

16 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

7 Drugs in Development

FINISHED DOSAGE FORMULATIONS

291 FDF Dossiers

34 FDA Orange Book

148 Europe

7 Canada

9 South Africa

93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML

FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

RELATED EXCIPIENT COMPANIES

3 Evonik

4 Rochem International Inc

20 SPI Pharma

9 DKSH

1 Pharm-RX Chemical

3 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

2 Pfanstiehl

4 Kirsch Pharma

1 ACG Worldwide

8 Actylis

2 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Avesta Pharma

19 BASF

1 CD Formulation

2 Clariant

12 Corel Pharma Chem

3 DFE Pharma

1 Esteem Industries

2 Finar

9 Gangwal Chemicals

8 Ideal Cures

4 Ingredion Pharma Solutions

11 Kerry

2 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

14 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

1 Novo Excipients

1 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

20 Roquette

14 Seppic

8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

TABLET;ORAL - EQ 125MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 250MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 500MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons